CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 42,879	$ 42,857	$ 44,915
Costs and operating expenses:
Selling, general and administrative expenses	8,595	8,445	8,993
Research and development expenses	1,390	1,337	1,471
Restructuring and other costs	379	459	114
Total costs and operating expenses	35,542	35,998	36,522
Operating income	7,337	6,859	8,393
Interest income	1,078	879	272
Interest expense	(1,390)	(1,375)	(726)
Other income/(expense)	12	(65)	(104)
Income before income taxes	7,037	6,298	7,835
Benefit from/(provision for) income taxes	(657)	(284)	(703)
Equity in earnings/(losses) of unconsolidated entities	(42)	(59)	(172)
Net income	6,338	5,955	6,960
Less: net income (losses) attributable to noncontrolling interests and redeemable noncontrolling interest	3	(40)	10
Net income attributable to Thermo Fisher Scientific Inc.	$ 6,335	$ 5,995	$ 6,950
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 16.58	$ 15.52	$ 17.75
Diluted (in dollars per share)	$ 16.53	$ 15.45	$ 17.63
Weighted average shares
Basic (in shares)	382	386	392
Diluted (in shares)	383	388	394
Product revenues
Revenues
Total revenues	$ 25,034	$ 25,243	$ 28,548
Costs and operating expenses:
Cost of revenues	12,523	13,168	14,247
Service revenues
Revenues
Total revenues	17,845	17,614	16,367
Costs and operating expenses:
Cost of revenues	$ 12,654	$ 12,589	$ 11,697